Hangzhou Dac Biotechnology Co., Ltd.
Clinical trials sponsored by Hangzhou Dac Biotechnology Co., Ltd., explained in plain language.
-
Smart missile drug takes aim at Hard-to-Treat prostate cancer
Disease control Not yet recruitingThis study tests a new drug called DEC003M, which is designed to seek out and destroy prostate cancer cells by targeting a protein called PSMA. The trial enrolls adults with advanced prostate cancer that has stopped responding to standard hormone therapy. Researchers aim to find …
Phase: PHASE1 • Sponsor: Hangzhou DAC Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail takes aim at tough lung cancer
Disease control Not yet recruitingThis study tests an experimental drug called DXC006 combined with either an immunotherapy drug (toripalimab) or standard chemotherapy (carboplatin or cisplatin) in 200 people with small cell lung cancer. The goal is to find the safest dose and see if the combination shrinks tumor…
Phase: PHASE1, PHASE2 • Sponsor: Hangzhou DAC Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC